Skip to main navigation Skip to search Skip to main content

Assessment of the cPAS-based BGISEQ-500 platform for metagenomic sequencing

  • Chao Fang
  • , Huanzi Zhong
  • , Yuxiang Lin
  • , Bing Chen
  • , Mo Han
  • , Huahui Ren
  • , Haorong Lu
  • , Jacob M. Luber
  • , Min Xia
  • , Wangsheng Li
  • , Shayna Stein
  • , Xun Xu
  • , Wenwei Zhang
  • , Radoje Drmanac
  • , Jian Wang
  • , Huanming Yang
  • , Lennart Hammarström
  • , Aleksandar D. Kostic
  • , Karsten Kristiansen
  • , Junhua Li
  • BGI-Shenzhen
  • University of Copenhagen
  • Harvard University
  • Joslin Diabetes Center
  • Dana-Farber Cancer Institute
  • Zhejiang University
  • Clinical University Hospital
  • South China University of Technology

Research output: Contribution to journal › Comment/debate

166 Scopus citations

Abstract

Background: More extensive use of metagenomic shotgun sequencing in microbiome research relies on the development of high-throughput, cost-effective sequencing. Here we present a comprehensive evaluation of the performance of the new high-throughput sequencing platform BGISEQ-500 for metagenomic shotgun sequencing and compare its performance with that of 2 Illumina platforms. Findings: Using fecal samples from 20 healthy individuals, we evaluated the intra-platform reproducibility for metagenomic sequencing on the BGISEQ-500 platform in a setup comprising 8 library replicates and 8 sequencing replicates. Cross-platform consistency was evaluated by comparing 20 pairwise replicates on the BGISEQ-500 platform vs the Illumina HiSeq 2000 platform and the Illumina HiSeq 4000 platform. In addition, we compared the performance of the 2 Illumina platforms against each other. By a newly developed overall accuracy quality control method, an average of 82.45 million high-quality reads (96.06% of raw reads) per sample, with 90.56% of bases scoring Q30 and above, was obtained using the BGISEQ-500 platform. Quantitative analyses revealed extremely high reproducibility between BGISEQ-500 intra-platform replicates. Cross-platform replicates differed slightly more than intra-platform replicates, yet a high consistency was observed. Only a low percentage (2.02%-3.25%) of genes exhibited significant differences in relative abundance comparing the BGISEQ-500 and HiSeq platforms, with a bias toward genes with higher GC content being enriched on the HiSeq platforms. Conclusions: Our study provides the first set of performance metrics for human gut metagenomic sequencing data using BGISEQ-500. The high accuracy and technical reproducibility confirm the applicability of the new platform for metagenomic studies, though caution is still warranted when combining metagenomic data from different platforms.

Original languageEnglish
Pages (from-to)1-8
Number of pages8
JournalGigaScience
Volume7
Issue number3
DOIs
StatePublished - 1 Mar 2018
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • BGISEQ-500
  • Next-generation sequencing
  • Quantitative metagenomic analyses

Fingerprint

Dive into the research topics of 'Assessment of the cPAS-based BGISEQ-500 platform for metagenomic sequencing'. Together they form a unique fingerprint.

Cite this